BioLargo Inc. (BLGO:OTCQX) announced that its engineering division, BioLargo Engineering, Science & Technologies, Inc. (BLEST), has secured a US$1.2 million contract to design of a pilot-scale minerals processing facility aimed at the remediation and beneficial reuse of legacy mineral waste from a site in the western United States that has been historically impacted, according to an April 20 release.
Under this new contract, BLEST will utilize its unique proprietary and patented technology to transform non-hazardous waste materials into commercially valuable products, BioLargo said. The current contract focuses solely on the initial design phase, which includes developing a pilot plant to demonstrate and validate the essential manufacturing and processing capabilities needed for future scale-up. This design phase is slated to last about six months.
Should the pilot operations prove successful, plans are in place to expand this initiative into a full-scale commercial production facility, the company said. The entire development process, from the pilot design to full-scale production, is expected to unfold over two to three years, with potential for extended long-term operations depending on the outcomes of the pilot phase and other standard development considerations.
"This project exemplifies the growing importance of waste-to-value solutions in modern environmental management," BioLargo President and Chief Executive Officer Dennis P. Calvert said. "By transforming legacy waste streams into commercially valuable products, we are helping our clients turn environmental liabilities into economic opportunities. We view this engagement as the first step in what we expect to be a long-term collaboration — beginning with preliminary design, advancing through pilot validation, and ultimately leading to full-scale construction and production."
The pilot program is also designed to produce materials for customer evaluation, product qualification, and initial market development efforts, BioLargo said. Work on this project is set to begin immediately, following a milestone-based structure.
This initiative underscores BioLargo's commitment to expanding its role in sustainable minerals processing and environmental remediation, particularly through innovative solutions that promote a circular economy and address legacy waste challenges.
ViaCLYR™ Finding Success
BioLargo is also finding success with its Clyra Medical Technologies subsidiary and its ViaCLYR™ advanced wound irrigation solution.
At the Boswick Symposium in Maui, Hawaii, on January 28, Dr. Marcus Gitterle presented positive clinical experiences with the technology. Gitterle serves as the Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy at Christus Santa Rosa Hospital System in San Antonio, Texas. He shared findings from a multi-site evaluation of ViaCLYR™ involving about 36 cases across four wound clinics over four months. The cases included challenging scenarios such as diabetic foot ulcers, venous leg ulcers, pressure injuries, and complex surgical wounds.
Dr. Gitterle described the results as "remarkable" and "unusual," highlighting ViaCLYR™'s excellent safety profile, strong antimicrobial performance, and its ability to enhance healing. Notably, no adverse reactions were reported during the evaluation. He emphasized the significant clinical improvements observed, such as enhanced granulation velocity, rapid closure of sinus tracts, and a noticeable reduction in wound drainage. Patients with chronic, fibrotic wounds experienced rapid transformation to highly proliferative healing wounds, a result Dr. Gitterle found particularly striking given the severity and chronicity of the underlying diseases.
ViaCLYR™ utilizes Clyra's proprietary Copper-Iodine Complex Solution (CICS), known as Clyrasept™, which offers rapid, broad-spectrum antimicrobial activity while remaining biocompatible with human tissues. Key clinical observations included rapid reduction in wound fluid discharge, noticeable increase in healing activity early in treatment, rapid closure of wound tunnels, improved wound edge appearance, dramatic transformation of chronic, scarred wounds to actively healing wounds, and significant reduction in wound size and depth, especially in pressure injuries.
In February, BioLargo announced that Clyra had received its first commercial stocking order from Advanced Solution LLC for ViaCLYR™, marking the start of commercial distribution and signifying Clyra's transition from development-stage operations to generating initial revenue. This milestone is seen as the first of many planned commercial and revenue-related announcements as Clyra advances its market rollout.
ViaCLYR™ is described as a highly effective, tissue-safe, long-acting wound irrigation solution suitable for a wide range of acute and chronic wounds and burns. It is 510(k) cleared by the FDA and indicated for use in both acute and chronic wounds, boasting extremely high antimicrobial activity and sustained efficacy for up to 72 hours.
Analyst: Multiple Catalysts Across Multiple Platforms
1BioLargo, a technology incubator, is making significant progress in addressing critical healthcare and environmental challenges, according to Technical Analyst John Newell of John Newell & Associates. In a report for Streetwise Reports dated March 11, Newell highlighted BioLargo's advancements, particularly through its Clyra technology, which is gaining recognition in the healthcare sector. Clyra's technology is noted for its ability to effectively eliminate pathogens without harming human tissue, positioning it as a vital tool in combating hospital-acquired infections and antibiotic resistance.
BioLargo's approach involves advancing its proprietary technologies through scientific validation and partnering with established organizations to scale these innovations. The company's portfolio spans advanced water treatment, environmental remediation, odor and air quality control, long-duration energy storage, and medical technologies. Among these, Clyra Medical Technologies is particularly notable for its copper-iodine antimicrobial solutions that maintain effectiveness for up to 72 hours without causing cytotoxic damage. This feature is crucial for treating wounds and surgical infections.
Clyra's lead product, ViaCLYR, has received FDA 510(k) clearance, which has facilitated its commercial distribution through established medical device channels. The technology is protected by around 40 issued and pending patents and is available in various delivery formats, including liquids, powders, hydrogels, and antimicrobial dressings, Newell noted.
In addition to its medical innovations, BioLargo is developing a long-duration energy storage system called the Cellinity™ battery. This system is designed to overcome the limitations of lithium-ion batteries for grid-scale applications and is built from earth-abundant materials aimed at multi-decade durability. The company intends to license this technology and partner with manufacturing facilities for its production.
BioLargo presents itself as a Speculative Buy, he said, offering multiple potential catalysts across its technology platforms. The company's strategic approach to commercialization and partnership positions it well to capitalize on the growing needs for advanced healthcare solutions and sustainable energy storage.
Oak Ridge Financial Analyst Richard Ryan gave up an update on the stock on March 6.
"BLGO's business model is a hub and spoke format — invent/acquire a product, prototype/prove it out, partner with necessary thirrd parties, and commercialize," wrote Ryan, who gives the stock a Buy rating. "By commercializing technologies through operating subsidiaries, BLGO diversifies overall risk, maintains high levels of segment ownership while providing solutions to diversified, high-growth end markets."
The Catalyst: Mineral Processing Waste Worldwide
Nicholas LePan, writing for Elements on May 15, 2021, highlighted the environmental impact of mining, specifically focusing on the waste known as tailings, which are often stored in dams or ponds globally. Citing data from the International Council on Mining and Metals, the United Nations Environment Programme, and Principles for Responsible Investment, LePan noted that there are approximately 8,500 active, inactive, or closed tailings storage facilities worldwide. These facilities collectively contain about 217 cubic kilometers of tailings, which could form a cube 6 kilometers tall.
A report by Market Research Future detailed the financial scope of the Mining Tailings Management Market, which was valued at US$11.74 billion in 2024. It is projected to grow to US$12.23 billion in 2025 and further increase to US$18.36 billion by 2035, achieving a compound annual growth rate (CAGR) of 4.15% over the forecast period from 2025 to 2035.
Streetwise Ownership Overview*The report identified filtered tailings as the dominant market segment, while thickened tailings are noted as the fastest-growing segment due to their efficiency in resource recovery. The growth in this market is largely driven by increased environmental awareness and regulatory pressures, which are encouraging investments in sustainable mining practices.
The report also highlighted significant trends and developments within the Mining Tailings Management Market. There is a clear shift towards sustainable practices and the integration of advanced technologies in the sector. Geographically, North America remains the largest market, attributed to its stringent regulatory and environmental standards. However, the Asia-Pacific region is rapidly emerging as the fastest-growing market, driven by a growing demand for innovative and sustainable tailings management solutions.
Ownership and Share Structure2
About 13.57% of BioLargo is owned by insiders and management. They include Chief Science Officer Kenneth Code with 8.07%, CEO Calvert with 3.28%, and Director Jack Strommen with 1.52%.
About 0.04% is held by the institution First American Trust. The rest, 86%, is retail.
Its market cap is US$46.79 million, with about 320.47 million shares outstanding and about 276.31 million free-floating. It trades in a 52-week range of US$0.26 and US$0.14.
| Want to be the first to know about interesting Special Situations and Technology investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
- Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
- Disclosure for the quote from the John Newell article published on March 3, 2026
- For the quoted article (published on March 3, 2026), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
- Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
John Newell Disclaimer
As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.
- Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
